Kornimate/medical-research-clean huggingface dataset:
real-world experience of icis plus chemotherapy with or without radiotherapy for advanced escc.

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Summary: this study is a multi-center, non-interventional study. clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (escc) patients.

this study is a multi-center, non-interventional study. patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (escc) patients who were treated with chemotherapy combined with immunotherapy as 1st line treatment at approximately 5 institutions. the patients should have received at least 1 cycle of immunotherapy and chemotherapy with or without radiotherapy. based on these data, overall survival (os), progression free survival (pfs) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.

Eligibility criteria:
inclusion criteria: 1. pathologically diagnosed as esophageal squamous cell carcinoma; 2. the clinical stage is ivb stage, that is, non-regional lymph node metastasis and distant organ metastasis (ajcc8th) of esophageal carcinoma. 3. patients had received no previous systemic therapy 4. patients who had received at least one cycle of first-line chemotherapy combined with immunotherapy, received or did not receive radiotherapy; 5. complete medical records; 6. ecog0-2; exclusion criteria: 1. surgery for esophageal cancer; 2. esophageal fistulae due to infiltration of the primary tumour. 3. risk of gastrointestinal bleeding, oesophageal fistula or oesophageal perforation 4. those who have a history of autoimmune disease or have been treated with immunosuppressants within the last 3 months. 5. those who have received organ transplant surgery. 6. patients with a previous history of malignant tumor (skin basal cell carcinoma and cervical carcinoma in situ) survived tumor-free for 3 years after treatment. except for the above). 7. there are other serious diseases, such as myocardial infarction, cerebral infarction or severe cardiopulmonary insufficiency within 6 months
curcumin supplement in nonalcoholic fatty liver patients

Conditions: Type 2 Diabetes; Nonalcoholic Fatty Liver

Summary: the purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes. subjects will participate in 3 month, two group, randomized intervention, where one group (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare differences in outcomes between the two groups.


Eligibility criteria:
inclusion criteria: * patient diagnosed with type 2 diabetes based on ada definition or who only take oral antidiabetic drug; * cap score \>263. exclusion criteria: * taking any kind of antibiotics two weeks before recruitment; * history of alcohol consumption; * pregnancy or lactation; * professional athletes; * other liver disease (viral/etc); * high dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs; * a history of cardiovascular disease; * renal disease, celiac disease, cirrhosis; * history of upper gi surgery; * a history of hypothyroidism or cushing's syndrome; * history of drug dependence; * body mass index (bmi) ≥35 kg/m2; * a restrictive diet or weight change ≥ 5 kg during the 3months prior to study; * any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents during the study; * use of weight loss medications.
validation of the panic screening score in patient with unexplained chest pain

Conditions: Noncardiac Chest Pain; Panic Attack

Summary: panic-like anxiety ( panic attacks with or without panic disorder), a highly treatable condition, is the most prevalent condition associated with unexplained chest pain in the emergency department. panic-like anxiety may be responsible for a significant portion of the negative consequences of unexplained chest pain, such as functional limitations and chronicity. however, more than 92% of panic-like anxiety cases remain undiagnosed at the time of discharge from the emergency department. the 4-item panic screening score questionnaire was derived in order to increase the identification of panic-like anxiety in emergency department patients with unexplained chest pain. the goals of this prospective cohort study are to (1) refine the panic screening score; (2) validate the revised version of the panic screening score; (3) measure the reliability of the revised version of the panic screening score and (4) assess the acceptability of the instrument among emergency physicians.


Eligibility criteria:
inclusion criteria: presenting unexplained chest pain as defined by: * the absence of an identifiable cause (e.g., pneumothorax,pneumonia), * the absence of chest trauma, * the absence of new malignant cardiac arrhythmia, and * a score of 2 or less on the modified version of the thrombolysis in myocardial infarction score. exclusion criteria: * presence of a terminal illness; * presence of a severe communication problem that could interfere with the administration of the questionnaire; * presence of a psychotic state, a major cognitive deficit or other condition that could invalidate the interview; * being legally incompetent.
luteal phase supplementation with recombinant lh after gnrh agonist oocytes triggering in women at risk of ohss

Conditions: Ovarian Hyperstimulation Syndrome

Summary: the purpose of this study is to prove that luteal phase supplementation with recombinant lh can solve the luteal phase deficiency after gnrh agonist oocytes triggering in women at risk of ohss

the investigators enrolled patients, undergoing controlled ovarian stimulation for an ivf/icsi cycles, who on the day of oocytes triggering were at risk of ohss. these patients had an estradiol \> 4000 pg/ml and more than 24 follicles with a diameter greater than 12 mm. the investigators used 0,2 mg of triptorelin for the oocytes triggering and supplemented the luteal phase with recombinant lh at a dose of 75 ui twice/day for 10 days and vaginal gel progesterone and oral oestradiol for 14 days the investigators measured bhcg at 14 days from the pick up. in case of positive bhcg we have defined the ivf/icsi outcome: pregnancy rate and implantation rate.

Eligibility criteria:
inclusion criteria: * patients with an oestradiol \> 4000 pg/ml on the oocytes triggering day * patient with more than 24 follicles of diameter greater than 12 mm on the oocytes triggering day exclusion criteria: * patients with no risk of ohss on the oocytes triggering day * patients with an oestradiol \< 4000 pg/ml on the oocytes triggering day * patient with less than 24 follicles of diameter greater than 12 mm on the oocytes triggering day

Keywords: ohss oocytes triggering gnrh agonist triggering luteal phase supplementation recombinant lh
compassionate use of an intravenous fish oil emulsion in infants with cholestasis

Conditions: Parenteral Nutrition Associated Cholestasis

Summary: the study will evaluate the safety and efficacy of an intravenous fish oil emulsion (omegaven) in infants with parenteral nutrition associated cholestasis.


Eligibility criteria:
inclusion criteria: cholestasis defined as either * serum bilirubin \> 2mg/dl (two measurements at least 8d apart) that has not responded to 4 weeks of intralipid being reduced to 1 g/kg/d and trace minerals being limited to twice weekly, or * serum bilirubin \> 6 mg/dl (single measurement) and rising, in the absence of proven or suspected sepsis exclusion criteria: * age \> 1y at time that omegaven is started * not expected to survive at least 30 days * fish allergy in a first degree relative * hemodynamic instability * coagulopathy * not likely to require pn for \> 30d * not expected to survive \> 30d

Keywords: cholestasis pnac parenteral nutrition associated cholestasis pnald parenteral nutrition associated liver disease
development of preterm infant gut microbiome

Conditions: Premature Infants

Summary: this study aims to explore the developmental of the gut microbiome in preterm infants as they grow and mature

preterm birth, defined as childbirth occurring at less than 37 completed weeks, is a major determinant of neonatal mortality and morbidity and has long-term adverse consequences for health. the human microbiome is the collective genome of the immense ecosystem of trillions of microbes and is considered to have a coevolved relationship with the immune system and fundamental roles in multiple aspects of human physiology. little is known about the developmental of the gut microbiome in preterm infants as they grow and mature. one hundred premature infants born in rambam healthcare campus in haifa, israel, will be recruited to the study and 100 term healthy infants will be recruited as controls. infants born before 24 weeks of gestation or have birth weights of less than 400 g and infants with severe congenital anomalies will be excluded from the study. fecal samples will be collected during the hospital stay and in follow-up visits. blood samples will be taken during the hospital stay. the investigators will analyze the data from this clinical cohort using computational and experimental approaches for extracting novel information on microbiome composition and development, gene function, metabolic pathways and metabolite production.

Eligibility criteria:
inclusion criteria: * premature and term infants born in rambam healthcare campus in haifa, israel exclusion criteria: * infants born before 24 weeks of gestation or have birth weights of less than 400 g and infants with severe congenital anomalies will be excluded from the study.
a study of genetic and environmental factors and their effect on response to treatment with lucentis (ranibizumab) for wet amd

Conditions: Macular Degeneration

Summary: the purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to lucentis (ranibizumab) treatment. for example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than another patient with different genes.

age-related macular degeneration (amd) is the leading cause of blindness in the developed world. the advanced stages of the disease are characterized by the development of geographic atrophy or choroidal neovascularization, both of which result in significant loss of vision. development of intravitreal anti-vegf agents such as ranibizumab has significantly improved outcomes for the neovascular for of the disease. however, it is not possible to predict which individuals will respond to the treatment. the objective of this study is to establish the association between genetic factors and treatment response to intravitreal lucentis. this will be accomplished by snp-genotyping participants for amd-susceptibility and candidate angiogenesis-pathway genes, collecting environmental risk factor variables and evaluating clinical outcomes. the aim of this pharmacogenetics study will be to identify patients at the outset of their treatment that require more intensive therapy.

Eligibility criteria:
inclusion criteria: * all amd-related cnv lesion types will be included. * age \>50 years * the study eye must never have received treatment for neovascular amd * visual acuity in treatment eye must be between 20/30 and 20/320 (etdrs). exclusion criteria: * age \<50 years; * previous therapy in either eye for amd or other retinal disease which may be used in the treatment of amd; * choroidal neovascularization not from amd; * concomitant non-amd related maculopathy in study eye; * active treatment for neovascular amd in fellow eye; * acuity loss or central field loss from non-amd cause; * pigment epithelial detachment without evidence of cnv; * individuals in whom lucentis is contraindicated; * participation in another clinical trial in last three months * pregnancy (positive pregnancy test) or lactation * premenopausal women not using adequate contraception * prior enrollment in the study * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

Keywords: pharmacogenetics genetics treatment response amd wet amd age-related macular degeneration
intrapleural bevacizumab injection for malignant effusion in lung cancer

Conditions: Non-small Cell Lung Cancer; Malignant Pleural Effusion

Summary: malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. tumor angiogenesis is important in producing mpe. bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-vegf mechanism. so we hypothesize that intrapleural bevacizumab is also effective in treating mpe.

inclusion criteria: 1. histological or cytological diagnosis of non-small cell lung cancer. 2. cytological diagnosis of malignant pleural or pericardial effusion (mpe) 3. symptomatic mpe evaluated by researchers 4. unsuitable for or reject systemic therapy of tumor 5. continuous tki treatment after tki-resistance 6. estimated survival of more than 3 months. 7.18 years or older exclusion criteria: 1. current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants 2. be allergic to bevacizumab 3. pregnant or lactating woman 4. pleural or pericardial infection

Eligibility criteria:
inclusion criteria: 1. histological or cytological diagnosis of non-small cell lung cancer. 2. cytological diagnosis of malignant pleural or pericardial effusion (mpe) 3. symptomatic mpe evaluated by researchers 4. unsuitable for or reject systemic therapy of tumor 5. estimated survival of more than 3 months. 6.18 years or older exclusion criteria: 1. current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants 2. be allergic to bevacizumab 3. pregnant or lactating woman 4. pleural or pericardial infection

Keywords: non-small cell lung cancer malignant pleural effusion bevacizumab intrapleural injection pericardial effusion
changes in auditory verbal hallucination during atypical antipsychotic treatment of patients with schizophrenia

Conditions: Schizophrenia; Hallucinations

Summary: the purpose of this study is to evaluate the changes in various aspects of auditory verbal hallucinations during 24-week antipsychotic treatment in naturalistic condition.

auditory verbal hallucinations (avh), meaning the experience of hearing voices, occur in 60-75% of patients with schizophrenia. patients experiencing persistent avh tend to be interrupted in their daily routines and have trouble keeping regular jobs due to the intrusiveness or abusive contents of voices. in addition, auditory hallucinations are reported to remain even after disappearance of other psychotic symptoms in many patients with schizophrenia spectrum disorders after treatment with typical antipsychotics. the study involves detailed phenomenological assessments of avh and other psychotic symptoms, as well as side effects of atypical antipsychotics.

Eligibility criteria:
inclusion criteria: * male or female patients, 15-65 years of age * patients must have a diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv)\> * patients experiencing vivid avh confirmed by score of 4 or above using hallucinatory behavior item on positive and negative syndrome scale (panss). * patients who are drug-naive or drug-free for more than 4 weeks. * patients who are scheduled to receive atypical antipsychotic medication. * each patient must provide written informed consent after full explanation of study protocol, and authorized legal guardian must understand the nature of the study and must also give assent to study participation. * subjects who are fluent in korean. exclusion criteria: * dsm-iv substance (except nicotine or caffeine) dependence within the past 1 year. * mental retardation (iq \< 70). * neurological disorders including epilepsy, stroke, or severe head trauma. * clinically significant laboratory abnormalities, on any of the following tests: cbc with differential, electrolytes, bun, creatinine, hepatic transaminases, urinalysis and ekg. * treatment with an injectable depot neuroleptic within less than three dosing interval between the last depot neuroleptic injections and baseline. * history of electroconvulsive therapy or transcranial magnetic stimulation within the past 3 months. * subjects who are not fluent in korean.

Keywords: schizophrenia auditory verbal hallucination antipsychotic treatment
impact of fourier transform infrared spectroscopy (ftirs) in icus

Conditions: Organ Failure, Multiple

Summary: this study will assess the impact of ftirs typing on the spread of esbl-e in intensive care units

multidrug resistant enterobacterales (mdr-e) are a major threat for patients hospitalized in intensive care units (icus). to prevent mdr-e spread in icus, rectal swabs are routinely performed and cultured on selective media. however, bacterial identification and antimicrobial susceptibility results are not sufficient to diagnose cross transmissions. the gold standard technique is based on genomic analysis that require whole genome sequencing (wgs) of bacteria and followed by multilocus sequence typing (mlst) and single nucleotide polymorphism (snp) typing. this technology is rather expensive and not applicable in all centers. fourier transform infrared spectroscopy (ftirs) is a developing method for rapid bacterial typing. this technology is simple and results can be obtained in one hour. it is therefore adapted to continuous surveillance of mdr-e. in france, extended spectrum betalactamase producing enterobacteriaceae (esbl-e) represent the vast majority of mdr-e. we postulate that early diagnosis of cross-transmission by ftirs may prevent the spread of esbl-e in icus and favor compliance with hygiene measures. the aim of this study will be to assess the impact of systematic ftirs typing of esbl-e on esbl-e cross-transmissions in icus.

Eligibility criteria:
inclusion criteria: * adult patients hospitalized in icu * esbl-e carrier exclusion criteria: * none

Keywords: multidrug resistant bacteria outbreak prevention and infection control bacterial typing fourier transform infrared spectroscopy
the combined use of indoor residual spraying (irs) and long-lasting insecticidal nets (llins) for malaria prevention

Conditions: Malaria

Summary: the study is a cluster randomised trial to compare the effectiveness of indoor residual spraying (irs) combined with the use of long lasting insecticidal nets (llins) with the effectiveness of llins alone for preventing malaria infection and morbidity. the primary outcome measure is prevalence of parasitaemia and anaemia in children aged 0.5-10 years, measured in cross sectional surveys. secondary outcomes include relative population density for each mosquito vector species, malaria transmission as measured by entomological inoculation rates (eir) by mosquito vector species, monitoring of resistance markers including kdr, and user acceptability of llins compared with irs. findings from this study are expected to inform decision making so that resource utilization can be optimised.


Eligibility criteria:
inclusion criteria: * resident in selected cluster (village) exclusion criteria: * not resident in selected cluster (village)

Keywords: vector control llin irs
fmri and ivcm cornea microscopy of cxl in keratoconus

Conditions: Pain, Postoperative; Pain, Chronic; Pain, Acute; Surgical Injury; Surgical Wound; Cornea Injury; Cornea; Keratoconus

Summary: evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (cxl) in keratoconus patients using fmri and corneal in vivo confocal microscopy (ivcm).

our long-term goal is to evaluate the transition from acute to chronic pain that sometimes occurs following cxl in keratoconus patients. this study will determine whether these changes can be structurally and functionally quantified using functional neuroimaging and in vivo corneal microscopy (ivcm), and whether they can be predicted based on predisposing biological and psychological factors. our central hypothesis is that cxl produces acute pain through activation of trigeminal afferents, and that post-operative chronic pain outcomes are related to neuroplastic changes in trigeminal circuitry, corneal afferent regeneration, and psychological factors.

Eligibility criteria:
inclusion criteria: cxl group * age 8-35 years * clinical diagnosis of keratoconus and seeking cxl treatment * english speaking ability sufficient to comprehend consent with parental assistance * mri compatible * ability to lie still for an mri session (60 minutes) control group * age 8-35 years * no diagnosis of keratoconus * english speaking ability sufficient to comprehend consent with parental assistance * mri compatible * ability to lie still for an mri session (60 minutes) exclusion criteria (both groups): * claustrophobic * weight \> 285 lbs (weight limit of the mri table) * significant medical history, including: current dsm-iv-tr axis i psychiatric disorders. chronic pain significant head injury seizures brain tumor cerebrovascular accident neurological disease aside from migraine hiv-aids prescription medication strongly implicated in causing dry eyes * magnetic implants or metal-containing tattoos on their chest or above * pregnancy * history of contact lens wear * any allergic response to a numbing eyedrop in the past

Keywords: fmri corneal microscopy ivcm neuroimaging
neurodynamic sliders promote flexibility in tight hamstring syndrome

Conditions: Hamstring Injury; Neurodynamics; Range of Motion

Summary: the goal of this study is to explore the intervention effect of home-based neurodynamic slider program on hamstring flexibility. fifty physically active male subjects will be randomly assigned to either performing a neurodynamic sliding technique (3x20 reps) or a static stretching protocol (3x30") on a daily basis for a 6-week period. hamstring flexibility will be assessed by means of the straight leg raise at baseline, immediately after the intervention and after 4 weeks follow up.


Eligibility criteria:
inclusion criteria: * male * aged between 18-30yrs * recreationally/competitively active * limited hamstring flexibility (tight hamstring syndrome) (slr≤75°) exclusion criteria: * a history of any musculotendinous hamstring injury in the previous year * a history of neurological or orthopedic disorder affecting the lower extremities * a history of lumbar disc herniation; or (4) a history of a cervical whiplash injury
efficacy and safety of diclofenac sodium gel in hand osteoarthritis

Conditions: Osteoarthritis

Summary: this study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of hand osteoarthritis.


Eligibility criteria:
key inclusion criteria: • osteoarthritis of the hand key exclusion criteria: * other rheumatic disease, such as rheumatoid arthritis * active gastrointestinal ulcer during the last year * known allergy to analgesic drugs

Keywords: hand osteoarthritis, topical nsaid, diclofenac sodium